Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-In-Human Study evaluating Fibroblast growth factor 1 for the treatment of Parkinson's disease

Next Previous
Trial Profile

A First-In-Human Study evaluating Fibroblast growth factor 1 for the treatment of Parkinson's disease

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 19 Dec 2022 According to a Zhittya Genesis Medicine media release, company will be hosting a webinar on Tuesday, December 20, 2022 to present data on the first Parkinson Disease patients dosed with FGF-1 in May 2022, who have reached their 6-month follow-up examinations.
  • 19 Dec 2022 Results presented in a Zhittya Genesis Medicine Media Release.
  • 16 Jun 2022 According to a Zhittya Genesis Medicine media release, company will be hosting a free Zoom webinar on June 23, 2022 to discuss the results of this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top